Four-factor Prothrombin Complex Concentrate During Liver Transplantation: A Retrospective Cohort Study.

BACKGROUND

Four-factor prothrombin complex concentrate (PCC) is a plasma product that contains factors II, VII, IX, X, protein C, and protein S. PCC can be used off-label to treat coagulopathy during orthotopic liver transplantation (OLT). However, its use comes with safety concerns regarding thrombosis. The purpose of our study is to determine the safety of PCC in OLT.

METHODS

We conducted a retrospective cohort study of patients who received 4-factor PCC during OLT at our institution from January 1, 2018, to May 1, 2022, with a 1:1 match of 83 patients who received PCC and 83 patients who did not. We evaluated 30-d mortality, 1-y mortality, prevalence of thrombotic complications (portal vein thrombosis, deep venous thrombosis, myocardial infarction, and pulmonary embolus), and postoperative intensive care (ICU) length of stay (LOS).

RESULTS

There was no significant difference in 30-d mortality (odds ratio [OR] 5; 95% confidence interval [CI], 0.58-42.8;  = 0.14), 1-y mortality (OR 3; 95% CI, 0.61-14.86;  = 0.18), or ICU LOS (OR -13.8; 95% CI, -39.2 to 11.6;  = 0.29). There was no increased incidence of thrombotic complications among patients receiving PCC 90 d after surgery, including portal vein thrombosis (OR 1.5; 95% CI, 0.42-5.32;  = 0.53), pulmonary embolus (OR 1; 95% CI, 0.14-7.1;  = 0.99), deep venous thrombosis (OR 0.67; 95% CI, 0.11-3.99;  = 0.66), and myocardial infarction (OR 1.67; 95% CI, 0.4-6.97;  = 0.48).

CONCLUSIONS

Although there was a statistically insignificant increase in mortality after PCC administration during OLT, we did not see a significant increase in perioperative complications, including thrombotic events and increased ICU LOS.